Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Bio-Path Stock Up 10.0 %

Shares of Bio-Path stock opened at $0.17 on Friday. The company has a fifty day moving average price of $0.21 and a 200 day moving average price of $0.67. Bio-Path has a twelve month low of $0.12 and a twelve month high of $4.57.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.